Very excited about our latest publication in Movement Disorders. This publication describes results from first-in-human and first-in-patient studies of LRRK2 inhibitor BIIB122 (DNL151). This is a great example of the use of pharmacodynamic biomarkers to explore the dose-response curve in early stage clinical development. Congratulations to the team of scientists and clinicians! We are very much looking forward to future read-outs of the two ongoing late-stage studies currently being conducted the Phase 2b LUMA study and the Phase 3 LIGHTHOUSE study for people with Parkinson's Disease with and without pathogenic variants of LRRK2. Read more here.
